CRDF - Cardiff Oncology, Inc. Common Stock

Day	1m	10m	60m	PreMarket	Market	AfterHours	Gap
2.27 0.14 (6.17%)	---	---	---	0.03 (1.32%)	0.11 (5.02%)	0.02 (1.04%)	0.02 (1.04%)

Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.

Category: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

Market Period: Closed

Earnings & Ratios

Basic EPS:: -0.21
Diluted EPS:: -0.21
Basic P/E:: -11.4762
Diluted P/E:: -11.4762
RSI(14) 1m:: 100.0
VWAP:: 2.41
RVol:: 1.6129

Events

Period	Kind	Movement	Occurred At
1m	Price decrease 1m	2.42 -0.02 (-1.02%)	Oct 15 10:10
10m	Price increase 10m	2.36 +0.07 (+3.06%)	Oct 15 09:36
1m	Price increase 1m	2.35 +0.03 (+1.3%)	Oct 15 09:31
1m	Price decrease 1m	2.29 -0.05 (-2.14%)	Oct 15 09:11
60m	Price increase 60m	2.39 +0.12 (+5.29%)	Oct 15 08:23